Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheon Revives Failed Alzheimer's Drug With Genetic Subtype Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.

Advertisement

Related Content

Where Is The Patient Voice In Alzheimer's Disease Drug Development?
Alzheimer’s Drugs Take Baby Steps Toward Brighter Future
Alzheon Inc.
Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079200

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel